- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01959971
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol
Primary Objective:
To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein (LDL) in adults with mildly elevated LDL-cholesterol (LDL-C).
Secondary Objectives:
To assess the effects of SC doses of alirocumab on:
- Various parameters of the metabolism and turnover in plasma of different lipoproteins
- Plasma lipids concentration: total cholesterol, high density lipoprotein cholesterol (HDL-C), triglycerides, low density lipoprotein cholesterol (LDL-C), apoB, lipoprotein(a) (Lp(a))
- Lipoprotein particle size profile
- PCSK9 (free and total) concentrations in serum To assess safety and tolerability of alirocumab. To assess emergence of anti-alirocumab antibodies. To document serum alirocumab concentrations.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Investigational Site Number 840001
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
Generally healthy; LDL-C level in serum or plasma ≥ 100 mg/dL and < 190 mg/dL at Screening.
Exclusion criteria:
- LDL-C ≥ 160 mg/dL at Screening if more than 2 major Coronary Heart Disease risk factors, as defined in National Cholesterol Education Program guidelines.
- Receiving treatment of any kind for hyperlipidemia within 6 weeks of enrollment.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Placebo - Alirocumab
Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
|
Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Andre navne:
Pharmaceutical form:Solution for injection Route of administration: Subcutaneous |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment
Tidsramme: baseline and at 12 days after last dose of alirocumab
|
baseline and at 12 days after last dose of alirocumab
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)
Tidsramme: baseline and at 12 days after last dose of alirocumab
|
baseline and at 12 days after last dose of alirocumab
|
Change in post-heparin hepatic lipase and lipoprotein lipase activities
Tidsramme: baseline and at 2 days after last dose of alirocumab
|
baseline and at 2 days after last dose of alirocumab
|
Change in lipids and apolipoproteins in plasma lipids panel
Tidsramme: baseline and at 2 days and at 11 days after last dose of alirocumab
|
baseline and at 2 days and at 11 days after last dose of alirocumab
|
Assessment of Lipoprotein particle size profiles
Tidsramme: baseline and at 2 days and at 11 days after last dose of alirocumab
|
baseline and at 2 days and at 11 days after last dose of alirocumab
|
Assessment of serum concentrations of PCSK9
Tidsramme: baseline and up to 2 weeks after last dose of alirocumab
|
baseline and up to 2 weeks after last dose of alirocumab
|
Assessment of safety parameters (clinical laboratory, ECG, vital signs)
Tidsramme: up to 10 weeks after last dose of alirocumab
|
up to 10 weeks after last dose of alirocumab
|
Assessment of the serum concentration of alirocumab
Tidsramme: baseline and up to 2 weeks after last dose of alirocumab
|
baseline and up to 2 weeks after last dose of alirocumab
|
Assessment of the serum concentration of anti-alirocumab antibodies
Tidsramme: baseline and up to 10 weeks after last dose of alirocumab
|
baseline and up to 10 weeks after last dose of alirocumab
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PDY13670
- U1111-1141-4567 (Anden identifikator: UTN)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med alirocumab
-
Fundación Hipercolesterolemia FamiliarAfsluttetFamiliær hyperkolesterolæmiSpanien
-
Westside Medical Associates of Los AngelesRegeneron Pharmaceuticals; University of WashingtonUkendtÅreforkalkning | HyperlipidæmiForenede Stater
-
Population Health Research InstituteAfsluttetST Elevation Myokardieinfarkt | Dyslipidæmi | Hyperkolesterolæmi | Hyperlipidæmi | Akut koronarsyndrom | Lægemidlers fysiologiske virkningerCanada
-
Shanghai Tong Ren HospitalChina Cardiovascular AssociationRekrutteringAkut myokardieinfarktKina
-
Regeneron PharmaceuticalsSanofiAfsluttetHyperkolesterolæmiForenede Stater, Bulgarien, Chile, Estland, Japan, Mexico, Den Russiske Føderation, Sydafrika, Ukraine
-
University of VirginiaNorthwestern UniversityAfsluttetPerifer arteriel sygdomForenede Stater
-
Regeneron PharmaceuticalsSanofiAfsluttetHeterozygot familiær hyperkolesterolæmi | Ikke-familiær hyperkolesterolæmiForenede Stater, Bulgarien, Estland, Den Russiske Føderation, Sydafrika, Ukraine
-
Washington University School of MedicineAfsluttet
-
University Hospital Inselspital, BerneRegeneron PharmaceuticalsAfsluttetKoronar Cirkulation | Atherom; Myokardie | KoronarkarDanmark, Schweiz, Østrig, Holland
-
Regeneron PharmaceuticalsSanofiAfsluttetHeterozygot familiær hyperkolesterolæmiForenede Stater, Tyskland